Valore202020212022202320242025TTMSpese di vendita, generali e amministrative36.82 M56 M59.54 M62.58 M48.45 M41.02 M41.02 MRicerca e sviluppo76.96 M104.4 M137.17 M180.43 M252.04 M166.42 M166.42 MReddito operativo-71.06 M-98.52 M-128.94 M-89.28 M-238.45 M-158.37 M-158.37 MProventi non operativi, Totale1.51 M577 K3.46 M14.51 M18.64 M9.25 M9.25 MOneri finanziari, al netto degli interessi capitalizzati2.3 M2.6 M2.4 M1.3 M———Proventi non operativi, esclusi gli oneri finanziari-792 K-2.02 M1.05 M13.21 M18.64 M9.25 M9.25 MEntrate/uscite straordinarie———————Utile al lordo delle imposte-71.85 M-100.55 M-116.7 M-88.6 M-225.1 M-191.18 M-191.18 MQuota di utile———————Imposte100 K02.5 M18.19 M2.36 M-93 K-93 KInteressi di minoranza———————Altri proventi/oneri al netto delle imposte-587 K-1.24 M-326 K-622 K-766 K-571 K-571 KUtile netto al lordo delle attività cessate-32.13 M-105.54 M-119.2 M-106.79 M-227.46 M-191.09 M-191.09 MAttività cessate———————Utile netto-32.13 M-105.54 M-119.2 M-106.79 M-227.46 M-191.09 M-191.09 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-32.13 M-105.54 M-119.2 M-106.79 M-227.46 M-191.09 M-191.09 MUtile base per azione (EPS base)——-23.5-17.8-29.6-22.49-22.49Utile diluito per azione (EPS diluito)——-23.5-17.8-29.6-22.49-22.49Numero medio di azioni ordinarie in circolazione——5.07 M6.02 M7.68 M8.5 M33.75 MAzioni diluite in circolazione——5.07 M6.02 M7.68 M8.5 M33.75 MEBITDA-66.76 M-93.68 M-123.25 M-82.46 M-231.24 M-151.04 M-151.04 MEBIT-71.06 M-98.52 M-128.94 M-89.28 M-238.45 M-158.37 M-158.37 MCosto del fatturato———————Altri costi del venduto———————Ammortamento e svalutazione (liquidità)4.3 M4.84 M5.69 M6.82 M7.22 M7.32 M7.32 M
Sutro Biopharma Inc
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.